Clearmind Medicine Inc (CMND)
$1.28
Performance
- $1.18$1.29$1.28
7.66%
Downside
Day's Volatility :8.37%
Upside
0.78%
- $0.13$13.76$1.28
90.22%
Downside
52 Weeks Volatility :99.09%
Upside
90.7%
Returns
| Period | Clearmind Medicine Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 23.97% | 0.0% |
6 Months | -7.25% | 0.0% |
1 Year | -90.41% | 0.0% |
3 Years | -99.28% | -22.3% |
Highlights
Market Capitalization | 5.2M |
Book Value | $1.4 |
Earnings Per Share (EPS) | 7.87 |
PE Ratio | 0.16 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -46.34% |
Return On Equity TTM | -173.29% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -5.5M |
Diluted Eps TTM | 7.87 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
Technicals Summary
Sell
Neutral
Buy
Clearmind Medicine Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Clearmind Medicine Inc | -0.78% | -7.25% | -90.41% | -99.28% | -99.28% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Clearmind Medicine Inc | 0.16 | 0.16 | NA | 0.0 | -1.73 | -0.46 | NA | 1.4 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Clearmind Medicine Inc | NA | $5.2M | -99.28% | 0.16 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Clearmind Medicine Inc
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 127.5%
Institutional Holdings
AdvisorShares Investments, LLC
2.78%Susquehanna International Group, LLP
0.59%Cornerstone Wealth Group, LLC
0.49%Geode Capital Management, LLC
0.40%Royal Bank of Canada
0.01%
Company Information
Organization | Clearmind Medicine Inc |
Employees | 0 |
CEO | Dr. Adi Zuloff-Shani Ph.D. |
Industry | Financial Conglomerates |
Discover More
A Spac I Acquisition Corp
$1.28
-0.78%
Keyarch Acquisition Corp
$1.28
-0.78%
Connexa Sports Technologies Inc
$1.28
-0.78%
Us Value Etf
$1.28
-0.78%
First Wave Biopharma Inc
$1.28
-0.78%
Global X Msci Next Emerging
$1.28
-0.78%
Fat Projects Acquisition Corp
$1.28
-0.78%
Capital Link Global Fintech
$1.28
-0.78%
Applied Uv Inc
$1.28
-0.78%